Neuroprotection in Huntington's disease: A 2-year study on minocycline

International Clinical Psychopharmacology

Volumn 19, Issue 6, 2004, Pages 337-342

  Bonelli, Raphael M ^a   Hödl, Anna K ^a   Hofmann, Peter ^a   Kapfhammer, Hans Peter ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Depression; Huntington's disease; Minocycline; Neuroprotection; UHDRS

Indexed keywords

MINOCYCLINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUNTINGTON CHOREA; INDEPENDENCE SCALE; MALE; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; MOTOR DYSFUNCTION; NAUSEA; NEUROPROTECTION; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SURVIVAL; TOTAL FUNCTIONAL CAPACITY SCALE; TOTAL MOTOR SCORE;

ADULT; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; MINOCYCLINE; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS; PSYCHOMOTOR PERFORMANCE; TREATMENT OUTCOME;

EID: 8644235217     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200411000-00004     Document Type: Article

References (42)

1. Bachoud-Levi AC, Maison P, Bartolomeo P, Boisse MF, Dalla Barba G, Ergis AM, et al. (2001). Retest effects and cognitive decline in longitudinal follow-up of patients with early HD. Neurology 56:1052-1058.
2. Bamford KA, Caine ED, Kido DK, Cox C, Shoulson I (1995). A prospective evaluation of cognitive decline in early Huntington's disease: functional and radiographic correlates. Neurology 45:1867-1873.
3. Benton A, Hamsher KDS (1978). Multilingual Aphasia Manual. Iowa City, IA: University of Iowa.
4. Blass DM, Steinberg M, Leroi I, Lyketsos CG (2001). Successful multimodality treatment of severe behavioral disturbance in a patient with advanced Huntington's disease. Am J Psychiatry 158:1966-1972.
5. Bonelli RM, Heuberger C, Reisecker F (2003). Minocycline for Huntington's disease: an open label study. Neurology 60:883-884.
6. Bonelli RM, Wenning GK, Kapfhammer HP (2004). Huntington's disease: present treatments and future therapeutic modalities. Int Clin Psychopharmacol 19:51-62.
7. Burns A, Folstein S, Brandt J, Folstein M (1990). Clinical assessment of irritability, aggression, and apathy in Huntington and Alzheimer disease. J Nerv Ment Dis 178:20-26.
8. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, et al. (2000). Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nature Med 6:797-801.
9. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. (2004). Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363:2105-2115.
10. Feigin A, Kieburtz K, Bordwell K, Como P, Steinberg K, Sotack J, et al. (1995). Functional decline in Huntington's disease. Mov Disord 10:211-214.
11. Fernandez HH, Friedman JH, Grace J, Beason-Hazen S (2000). Donepezil for Huntington's disease. Mov Disord 15:173-176.
12. Folstein MF, Folstein SE, McHugh PR (1975). 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198.
13. Friedlander RM (2003). Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 348:1365-1375.
14. Hamilton JM, Salmon DP, Corey-Bloom J, Gamst A, Paulsen JS, Jerkins S, et al. (2003). Behavioural abnormalities contribute to functional decline in Huntington's disease. J Neurol Neurosurg Psychiatry 74:120-122.
15. Hersch S, Fink K, Vonsattel JP, Friedlander RM (2003). Minocycline is protective in a mouse model of Huntington's disease. Ann Neurol 54:841.
16. Huntington Study Group (1996). Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 11:136-142.
17. Huntington Study Group (2004). Minocycline safety and tolerability in Huntington disease. Neurology 63:547-549.
18. Ikemoto K (2004). Significance of human striatal D-neurons: implications in neuropsychiatric functions. Prog Neuropsychopharmacol Biol Psychiatry 28:429-434.
19. Joel D (2001). Open interconnected model of basal ganglia-thalamocortical circuitry and its relevance to the clinical syndrome of Huntington's disease. Mov Disord 16:407-423.
20. Lemiere J, Decruyenaere M, Evers-Kiebooms G, Vandenbussche E, Dom R (2004). Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation A longitudinal follow-up study. J Neurol 251:935-942.
21. Leroi I, O'Hearn E, Marsh L, Lyketsos CG, Rosenblatt A, Ross CA, et al. (2002). Psychopathology in patients with degenerative cerebellar diseases: a comparison to Huntington's Disease. Am J Psychiatry 159:1306-1314.
22. Levy ML, Cummings JL, Fairbanks LA, Masterman D, Miller BL, Craig AH, et al. (1998). Apathy is not depression. J Neuropsychiatry Clin Neurosci 10:314-319.
23. Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, et al. (2000). Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology 54:452-458.
24. Myers RH, Sax DS, Koroshetz WJ, Mastromauro C, Cupples LA, Kiely DK, et al. (1991). Factors associated with slow progression in Huntington's disease. Arch Neurol 48:800-804.
25. Naarding P, Kremer HP, Zitman FG (2001). Huntington's disease: a review of the literature on prevalence and treatment of neuropsychiatric phenomena. Eur Psychiatry 16:439-445.
26. Nehl C, Paulsen JS (2004). Cognitive and psychiatric aspects of Huntington disease contribute to functional capacity. J Nerv Ment Dis 192:72-74.
27. Norremolle A, Riess O, Epplen JT, Fenger K, Hasholt L, Sorensen SA (1993). Trinucleotide repeat elongation in the Huntingtin gene in Huntington disease patients from 71 Danish families. Hum Mol Genet 2: 1475-1476.
28. Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM, et al. (1999). Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399:263-267.
29. Paulsen JS, Ready RE, Hamilton JM, Mega MS, Cummings JL (2001). Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry 71:310-314.
30. Penney JB Jr, Young AB, Shoulson I, Starosta-Rubenstein S, Snodgrass SR, Sanchez-Ramos J, et al. (1990). Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 5:93-99.
31. Rot U, Kobal J, Sever A, Pirtosek Z, Mesec A (2002). Rivastigmine in the treatment of Huntington's disease. Eur J Neurol 9:689-690.
32. Shoulson I, Kurlan R, Rubin A (1989a). Assessment of functional capacity in neurodegenerative disorders: Huntington's disease as a prototype. In: Munsat TL (editor): Quantification of Neurologic Deficit. Boston, MA: Butterworth; pp. 285-309.
33. Shoulson I, Odoroff C, Oakes D, Behr J, Goldblatt D, Caine E, et al. (1989b). A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann Neurol 25:252-259.
34. Siesling S, van Vugt JP, Zwinderman KA, Kieburtz K, Roos RA (1998). Unified Huntington's disease rating scale: a follow up. Mov Disord 13: 915-919.
35. Smith A (1973). Symbol Digit Modalies Test Manual. Los Angeles, CA: Western Psychological Services.
36. Thomas M, Ashizawa T, Jankovic J (2004). Minocycline in Huntington's disease: a pilot study. Mov Disord 19:692-695.
37. Tikka TM, Koistinaho JE (2001). Minocycline provides neuroprotection against n-methyl-d-aspartate neurotoxicity by inhibiting microglia. J Immunol 166: 7527-7533.
38. Tost H, Wendt CS, Schmitt A, Heinz A, Braus DF (2004). Huntington's disease: phenomenological diversity of a neuropsychiatric condition that challenges traditional concepts in neurology and psychiatry. Am J Psychiatry 161: 28-34.
39. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr (1985). Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44:559-577.
40. Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, et al. (2003). Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci USA 100:10483-10487.
41. Yamamoto A, Lucas JJ, Hen R (2000). Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101:57-66.
42. Young AB, Shoulson I, Penney JB, Starosta-Rubinstein S, Gomez F, Travers H, et al. (1986). Huntington's disease in Venezuela: neurologic features and functional decline. Neurology 36:244-249.